Method, reagent and kit for the detection of fecal occult blood

Information

  • Patent Grant
  • 5563071
  • Patent Number
    5,563,071
  • Date Filed
    Friday, May 12, 1995
    29 years ago
  • Date Issued
    Tuesday, October 8, 1996
    28 years ago
Abstract
A fecal specimen may be tested for the presence of occult blood by combining the fecal specimen with(a) an oxidizable substrate that produces a colored product in the presence of peroxide and hemoglobin;(b) hydrogen peroxide or a peroxide source; and(c) an enhancer selected to enhance the sensitivity of the test. Suitable enhancers are monocyclic nitrogen-containing aromatic heterocyclic compounds; tertiary or quaternary ammonium compounds having a phenyl, hydroxy alkyl or esterified hydroxy alkyl attached to the nitrogen; or quinoline or a substituted derivative thereof. If hemoglobin is present in the fecal sample, the oxidizable substrate is converted to the visibly detectable, colored product.
Description

This invention relates to the detection of fecal occult blood, and in particular to the use of enhanced developers in the detection of fecal occult blood.
Fecal occult blood may provide a reliable diagnostic indicator of a variety of medical conditions involving gastrointestinal bleeding which may otherwise be difficult to detect, including colorectal cancer. The use of this method is well described in the medical literature. See e.g., Greegor, D. H., Cancer 19:330-337 (1969) and Hastings, J. B., Amer. J. Surg. 127:228-233 (1974). Tests for fecal occult blood based upon the oxidation of guaiac to form a blue colored product in the presence of hydrogen peroxide and hemoglobin have been described in U.S. Pat. No. 3,996,006, incorporated herein by reference. Such products are sold under the trademarks HEMOCCULT.RTM. AND SERACULT.RTM.. Briefly, the test involves placing a fecal sample on an absorbent paper coated with guaiac and adding a developer solution containing hydrogen peroxide. If hemoglobin is present, the guaiac is oxidized, turning the paper blue.
It is considered desirable to increase the sensitivity of the test in order to detect excessive blood loss into the bowel at the earliest possible stage. The occurrence of false negatives, the problem of not detecting the presence of blood, is thus detrimental. Attempts have therefore been made to increase the sensitivity of the test. For example, the addition of a drop or two of water to the fecal smear on the guaiac impregnated test paper prior to the addition of the peroxide solution has been used to enhance the test sensitivity. Such procedures frequently give a positive reaction even if there is no pathologically significant amount of blood present in the stool. The occurrence of false positives is also undesirable, since it can lead to unnecessary follow-up medical procedures.
An improved version of this test is described in European Patent Publication No. 0 308 227. Phenols are added to the developer solution to achieve an enhancement of the amount of colored product produced, resulting in a more sensitive assay.
SUMMARY OF THE INVENTION
It has now been found that compounds other than phenols, specifically tertiary and quaternary nitrogen compounds, can be used to enhance the sensitivity of a test for fecal occult blood. It is therefore an object of the present invention to provide an enhanced method for testing of fecal occult blood that makes use of (1) monocyclic nitrogen-containing aromatic heterocyclic compounds such as triazole, pyridine, pyrazine or substituted derivatives thereof; (2) tertiary or quaternary ammonium compounds containing at least one hydroxy alkyl or esterified hydroxy alkyl group or a phenyl or substituted phenyl group to the nitrogen or (3) quinoline or a substituted derivative thereof to enhance the sensitivity of the test.
It is a further object of the invention to provide a developer solution containing an enhancer in accordance with the invention together with peroxide in an ethanol water carrier for use in testing for fecal occult blood.
It is still a further object of the invention to provide a kit for testing for fecal occult blood. Such a kit includes an enhanced developer composition containing an enhancer according to the invention and an oxidizable substrate such as guaiac.





DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, a fecal specimen may be tested for the presence of occult blood by combining the fecal specimen with
(a) an oxidizable substrate that produces a colored product in the presence of peroxide and hemoglobin;
(b) hydrogen peroxide or a peroxide source; and
(c) an enhancer selected from the group consisting of monocyclic nitrogen-containing aromatic heterocyclic compounds or tertiary or quaternary ammonium compounds which enhance the sensitivity of the test. If hemoglobin is present in the fecal sample, the oxidizable substrate is converted to the visibly detectable, colored product.
A preferred oxidizable substrate for use in accordance with the invention is guaiac which is the substrate used in commercially available test kits. Other substrates which are oxidized by peroxide in the presence of hemoglobin to produce a colored product that can be visually detected in the presence of fecal material may also be used. Suitable alternative materials include 3,3", 5,5-tetramethylbenzidine (see U.S. Pat. No. 4,562,043 incorporated herein by reference), guaiaconic acid A and other leuco dyes that are oxidized in the presence of peroxide and hemoglobin (see U.S. Pat. Nos. 4,219,336 and 4,971,914 incorporated herein by reference).
A simple and convenient way to conduct the test is to place the oxidizable substrate on a solid support. A preferred solid support is an absorptive paper which has been impregnated with the oxidizable substrate. The oxidizable substrate needs to be present in amounts sufficient to generate a detectable amount of colored product, generally above 0.5 gm/1000 in.sup.2. In the coated paper used in commercial kits today, this amounts to about 0.75 gm/1000 in.sup.2. Using a micropipet, a small (e.g. 0.03 ml) aliquot of the fecal specimen is placed on the support. One or two drops of developer solution are then added, and the extent of color development, if any, is observed.
This developer solution contains hydrogen peroxide or a source of peroxide such as cumene hydroperoxide and the enhancer in an ethanol/water carrier. The developer solutions of the invention generally contain 4 to 6% by weight of hydrogen peroxide, 0.2 to 4% by weight of the enhancer, and 80 to 90% ethanol with the balance being water. Preferably, the enhancer will be present in amounts of from 0.3 to 1.5% by weight, the exact amount depending on the specific enhancer being used. Unless limited by solubility considerations, higher enhancer concentrations can also be used but it will be appreciated that the resulting increase in sensitivity may lead to the detection of low levels of occult blood that are not medically significant, i.e., false positives.
Enhancers useful in the present invention include monocyclic nitrogen-containing aromatic heterocyclic compounds such as triazole, pyridine, pyrazine and substituted derivatives thereof, including 4-benzyl pyridine, 2-methoxy pyridine, 4-(p-nitrobenzyl) pyridine, and pyrazine carboxylic acid. Other enhancers in accordance with the invention are tertiary or quaternary amines having at least one hydroxy alkyl or esterified hydroxy alkyl group attached to the nitrogen. Examples of such enhancers include diethyl ethanolamine, ethyl diethanolamine and triethanolamine, acetylcholine chloride and .beta.-methyl acetylcholine chloride. A further class of enhancers in accordance with the present invention are tertiary and quaternary amines having a phenyl group attached to the nitrogen, e.g. dimethyl aniline. Quinoline and derivatives thereof such as alpha-hydroxy quinoline were also found to be effective enhancers.
EXAMPLE 1
Various compounds were tested for their ability to act as enhancers of guaiac oxidation by peroxide in the presence of hemoglobin. A sample of blood was diluted 1:20,000 to approximate the level of blood in a fecal sample and an 0.03 ml drop was placed onto a guaiac coated paper support of the type used in SERACULT.RTM. and SERACULT PLUS.RTM. test kits. 1-2 drops of a developer solution (0.04 to 0.1 ml) containing 4% H.sub.2 O.sub.2, 4% of a selected enhancer, 8% water and 84% ethanol was then placed on the paper support and observations for color formation were made. Each enhancer was rated on a scale of 1 to 4 for color formation, with 1 being the amount of color generated using no enhancer and 2 being the amount of color generated using 1.5% ethyl hydroxybenzoic acid (ethyl paraben), a phenolic enhancer of the type disclosed in EP 0 308 227 and used in commercial products. The results of these tests are shown in Table 1. In Table 1, an observable color intensity less than that of the unenhanced control is reported as TR.
During these tests, it was observed that the colored product produced varied in stability depending on the enhancer. The rate of fading is also reported in Table 1(VS=very slow, S=slow, M=moderate, F=fast). In general, a fade rate of moderate or slower is consistent with the ordinary period for observing the results of fecal occult blood tests of 30-120 seconds after testing.
TABLE 1______________________________________ ColorTest Enhancer Intensity FADE______________________________________2 - methoxy pyridine 3.5 S3 - hydroxypyridine 2.5 S3 - hydroxypyridine-N-oxide 1 S4 - benzyl pyridine 4 Spyridine 3.5 Spyrazine 4 S1,2,4 - triazole 3.5 Spyrazine carboxylic acid 4 Squinoline 3.5 S2 - amino pyridine tr F4 - (p-nitrobenzyl)-pyridine 3.5 S(light yellow)pyridine - HCl 2.5 Fdimethyl ethanolamine 3.5 Striethanolamine 1+ M-Sphenyl diethanolamine 3.5 S8-hydroxy quinoline 3 SComparative Compoundsphenyl salicylate 4 Ssalicylic acid tr Shydroquinone 0methylether hydroquinone tr Sdimethyl hydroquinone 1 Sp-phenyl phenol 2.5 VS1,2 - dimethoxyphenol tr Ssalicylamide 1.5 S______________________________________
EXAMPLE 2
An 0.03 ml drop of 1:30,000 diluted blood sample was placed on guaiac coated paper. One to two drops of a developer solution containing 84% ethanol, 4% hydrogen peroxide and 0.7% pyrazine carboxylic acid, the balance being water, was placed on the test paper. A blue coloration was observed where the blood sample had been placed on the test paper.
EXAMPLE 3
An 0.03 ml drop of a 1:30,000 dilution blood sample was placed on a guaiac-coated test paper. One to two drops of a developer solution containing 84% ethanol, 4% hydrogen peroxide, 0.5% 4-benzyl pyridine, the balance being water was then placed on the paper. A blue coloration was observed where the blood sample had been placed on the test paper.
EXAMPLE 4
Additional enhancers were tested using a 1:25,000 dilution of a blood sample. The results are summarized in Table 2.
TABLE 2______________________________________ ColorEnhancer Developed Comments______________________________________1% acridine 2 developer is yellow but does not disturb result1% dimethylethanolamine 2.51.3% 2.5diethylethanolamine4% diethylethanolamine 1.5 faded fast1% phenyldiethanolamine 41% dimethyl aniline 2.5 faded fast4% triethanolamine 14.3% acetyl choline 1.5chloride4% beta-methyl acetyl 1.5choline chloride4% acetyl choline .5bromideControlsSeracult <.5Seracult + 1.5% ethyl 1paraben______________________________________
EXAMPLE 5
Because peroxide may be lost from developer solutions on aging, developer solutions with lower levels of peroxide were tested. Three sets of developer solutions were prepared for each enhancer tested containing 2%, 3% and 4% hydrogen peroxide by mixing 44 grams ethanol, 0.04 g phosphoric acid, 0.3 to 2 grams of an enhancer and 0.32, 0.47. or 0.63 grams of peroxide and adding water to a total weight of 50. The results, summarized in Table 3, show that lower peroxide concentrations can be effectively used.
TABLE 3______________________________________ Peroxide Concentration Persistence ofEnhancer 4% 3% 2% Blue color______________________________________ethyl paraben 3+ 3+ 3+ slow fade(1.5%)benzophenone (4%) 1+ 1+ 1+ slow fadedimethyl 3+ 3+ 3+ fast fadeethanolamine (1%)benzyl pyridine 4+ 4+ 4+ medium fade(1%)pyrazine (1%) 4+ 4+ 4+ medium fadepyrazine 3.5+ 3.5+ 3.5+ slow fadecarboxylic acid(0.6%)______________________________________
EXAMPLE 6
To evaluate the storage stability of developer solutions according to the invention, developers containing various enhancers was refluxed for 48 or 65 hours and tested for the level of peroxide. The average starting peroxide level was 4.27% The samples which had been refluxed for 65 hours were also tested for their usefulness in developing a fecal occult blood test. The results, which are summarized in Table 4, show the stability of various enhancers in accordance with the invention, although triazole had poor results in this rather extreme test.
TABLE 4______________________________________ H.sub.2 O.sub.2 H.sub.2 O.sub.2 COLOR COLOR (%) (%) SCORE SCORE after 48 after 65 W/O W/Enhancer hours hours REFLUX REFLUX______________________________________1.23% 4-benzyl 3.48 3.25 4+ 3+pyridine 3.16 3.51% 4(p-nitro- 4.57 4.14 4+ 3+benzyl) pyridine 4.65 nddimethyl- nd 1.62 3+ 3+ethanolamine 1.93 1.571.1% 1,2,4 <.082 4+ 0triazolebenzophenone 1.74 nd 1+ 1+ 1.8 nd______________________________________
EXAMPLE 7
The test of Example 6 was repeated but with a 72 hour reflux period and different enhancers. The results are summarized in Table 5.
TABLE 5______________________________________ COLOR COLOR Initial H.sub.2 O.sub.2 (%) SCORE SCORE Peroxide after 72 W/O W/Enhancer (%) hours REFLUX REFLUX______________________________________0.6% pyrazine 4.27 4.14 3+ 2+carboxylic acid 4.27no enhancer 4.27 1.88 2+ 1+ 2.1Seracult .RTM. Plus 4.09 2.62 3+ 2+ 2.45SANSA .RTM. 4.11 2.97 2-3+ 2+(Lot 5017C) 2.95______________________________________
Claims
  • 1. A method for detecting occult blood in a specimen comprising combining the specimen with
  • (a) an oxidizable substrate that produces a colored product in the presence of peroxide and hemoglobin; and
  • (b) a liquid developer comprising hydrogen peroxide or a peroxide source, a carrier consisting essentially of water and ethanol, and an enhancer component, said enhancer component consisting of a material selected from the group consisting of tertiary and quaternary amines having a hydroxy alkyl or esterified hydroxy alkyl group attached to the nitrogen, wherein the oxidizable substrate and liquid developer are combined with the specimen in amounts effective to produce a visually detectable color change if medically significant amounts of blood are present in the specimen.
  • 2. A method according to claim 1, wherein the enhancer component is present in the carrier in amounts of from 0.2% to 4% by weight.
  • 3. A method according to claim 1, wherein the enhancer component is present in the carrier in amounts of from 0.3% to 1.5% by weight.
  • 4. A method according to claim 1, wherein the enhancer component is phenyl diethanolamine.
  • 5. A method according to claim 1 wherein the enhancer component is dimethyl ethanolamine.
  • 6. A composition for use as a developer in a test for occult blood based upon the oxidation of a substrate to a colored product comprising
  • (a) hydrogen peroxide or a peroxide source;
  • (b) an amount of an enhancer component effective to enhance the amount of colored product produced; and
  • (c) a carrier consisting essentially of water and ethanol, wherein the enhancer component consists of a material selected from the group consisting of tertiary and quaternary amines having a hydroxy alkyl or esterified hydroxy alkyl group attached to the nitrogen.
  • 7. A composition according to claim 6, wherein the enhancer component is present in amounts of from 0.2% to 4% by weight.
  • 8. A composition according to claim 7, wherein the peroxide is present in an amount of from 4% to 6% by weight.
  • 9. A composition according to claim 6, wherein the peroxide is present in an amount of from 4% to 6% by weight.
  • 10. A composition according to claim 6, wherein the enhancer component is phenyl diethanolamine.
  • 11. A composition according to claim 6, wherein the enhancer component is dimethyl ethanolamine.
  • 12. A kit for the detection of occult blood comprising, in packaged combination,
  • (a) an oxidizable substrate which is converted to a colored product in the presence of peroxide and hemoglobin; and
  • (b) a liquid developer comprising hydrogen peroxide or a peroxide source and an enhancer component in an amount effective to enhance the conversion of the oxidizable substrate to the colored product in a carrier consisting essentially of ethanol and water, wherein the enhancer component consists of a material selected from the group consisting of tertiary and quaternary amines having a hydroxy alkyl or esterified hydroxy alkyl group attached to the nitrogen.
  • 13. A kit according to claim 12, wherein the enhancer component is present in the developer in an amount of from 0.2% to 4% by weight.
  • 14. A kit according to claim 13, wherein the peroxide is present in the developer in an amount of from 4% to 6% by weight.
  • 15. A kit according to claim 12, wherein the peroxide is present in the developer in an amount of from 4% to 6% by weight.
  • 16. A kit according to claim 12, wherein the enhancer component is phenyl diethanolamine.
  • 17. A kit according to claim 12, wherein the enhancer component is dimethyl ethanolamine.
SPECIFICATION

This application is a divisional of U.S. patent application Ser. No. 08/121,072 filed Sep. 14, 1993, now U.S. Pat. No. 5,447,868 issued Sep. 5, 1995.

US Referenced Citations (54)
Number Name Date Kind
3290117 Adams et al. Dec 1966
3975161 Svoboda et al. Aug 1976
3986833 Mast et al. Oct 1976
3996006 Pagano Dec 1976
4017261 Svoboda et al. Apr 1977
4063894 Ogawa et al. Dec 1977
4071315 Chateau Jan 1978
4071317 Lam Jan 1978
4071318 Lam Jan 1978
4071321 Lam Jan 1978
4219336 Guthlien et al. Aug 1980
4220713 Rittersdorf Sep 1980
4247631 Nix et al. Jan 1981
4279993 Magers et al. Jul 1981
4290773 Magers et al. Sep 1981
4302537 G ubdermann et al. Nov 1981
4333734 Fleisher Jun 1982
4460684 Bauer Jul 1984
4486536 Baker et al. Dec 1984
4493892 Fleischer Jan 1985
4543338 Chen Sep 1985
4562043 Mennen et al. Dec 1985
4587220 Mayambala-Mwanika et al. May 1986
4615982 Lawrence Oct 1986
4645743 Baker et al. Feb 1987
4719181 Schobel et al. Jan 1988
4742002 Guadagno May 1988
4778753 Yamanishi et al. Oct 1988
4789629 Baker et al. Dec 1988
4818702 Lawrence Apr 1989
4820646 Lawrence Apr 1989
4828983 McClune May 1989
4891314 Pauly et al. Jan 1990
4895798 Charlton et al. Jan 1990
4920045 Okuda et al. Apr 1990
4937197 Lawrence Jun 1990
4939097 Lawrence Jul 1990
4942132 Lawrence Jul 1990
4971914 Lawrence Nov 1990
5013669 Peters, Jr. et al. May 1991
5053342 Lawrence Oct 1991
5064766 Wardlaw et al. Nov 1991
5068197 Lawrence Nov 1991
5081040 Patel et al. Jan 1992
5084382 Frey et al. Jan 1992
5084395 Bouse et al. Jan 1992
5089420 Albarella et al. Feb 1992
5094956 Grow et al. Mar 1992
5122451 Tanaka et al. Jan 1992
5178831 Sakota et al. Jan 1993
5196167 Guadagno et al. Mar 1993
5310680 Baker et al. May 1994
5391498 Baker et al. Feb 1995
5447868 Augurt Sep 1995
Foreign Referenced Citations (7)
Number Date Country
844973 Feb 1977 BEX
0253548 Jan 1988 EPX
0308227 Mar 1989 EPX
1147366 Jun 1989 JPX
1560077 Jan 1980 GBX
8603585 Jun 1986 WOX
8905972 Jun 1989 WOX
Non-Patent Literature Citations (1)
Entry
Abstract-JP 1-147366, Jun. 9, 1989. (Derwent-World Patent Index).
Divisions (1)
Number Date Country
Parent 121072 Sep 1993